Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 8/20 | 0.53 |
| ▸ | ACE | P12821 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9396607 | 0.88 | CPA3 (0.43) | CPA3FOLH1MMEACEALDH1A1 | |
| SCHEMBL7367991 | 0.88 | MME (0.57) | CPA3FOLH1MMEACEALDH1A1 | |
| SCHEMBL7368451 | 0.86 | MME (0.56) | CPA3FOLH1MMEACEALDH1A1 | |
| SCHEMBL28006830 | 0.85 | MMP8 (0.48) | CPA3FOLH1ALDH1A1MEN1KMT2A | |
| SCHEMBL7370831 | 0.82 | CYP1A2 (0.52) | MMEACEALDH1A1MEN1KMT2A | |
| SCHEMBL7287463 | 0.80 | MMP8 (0.51) | ALDH1A1MEN1MAPTKMT2AMMP8 | |
| SCHEMBL7288147 | 0.80 | CPA1 (0.53) | CPA3FOLH1MMEALDH1A1MEN1 | |
| SCHEMBL27563063 | 0.79 | MMP8 (0.50) | ALDH1A1MEN1KMT2AMMP8 | |
| SCHEMBL27563062 | 0.79 | MMP8 (0.50) | ALDH1A1MEN1KMT2AMMP8 | |
| SCHEMBL9396610 | 0.78 | MME (0.39) | MMEACEALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5403824-A | Administering a opioid, opioid-degrading enzyme inhibitor or enkephalin secretagogues or mixtures thereof; side effect reduction | THE PROCTER & GAMBLE COMPANY (US) | 1995-04-04 | — | — | US | claimed |
| WO-1994021242-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | THE PROCTER & GAMBLE COMPANY (US) | 1994-09-29 | — | — | WO | claimed |
| EP-0280627-B1 | DERIVATIVES OF N-SUBSTITUTED ALPHA-MERCAPTOMETHYL-BENZENE-PROPANAMIDE, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICINES AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1993-04-21 | — | — | EP | claimed |
| US-4839358-A | ANALGESICS, ANTIDEPRESSANTS, ANTIANXIETY AGENTS | ROUSSEL UCLAF (FR) | 1989-06-13 | — | — | US | claimed |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240165032-A1 | DRUG DELIVERY SYSTEM | EB IP HYBRITABS B V (NL) | 2024-05-23 | — | — | US | disclosed |
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230330028-A1 | PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS | EB IP HYBRITABS B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20040234518-A1 | Composition, methods and reagents for the synthesis of a soluble form of human PHEX | UNIVERSITE DE MONTREAL (CA) | 2004-11-25 | — | — | US | disclosed |
| US-6790649-B1 | PHEX GENE (PHOSPHATE REGULATING GENE WITH HOMOLOGIES TO ENDOPEPTIDASES ON X CHROMOSOME); FOR TREATMENT OF X-LINKED HYPOPHOSPHATEMIA (XLH), A PHOSPHATE HOMEOSTASIS DISORDER; RETARDATION, BONE, RENAL AND METABOLISM DISORDERS | UNIVERSITE DE MONTREAL (CA) | 2004-09-14 | — | — | US | disclosed |
| EP-1159412-A2 | COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX | UNIVERSITE DE MONTREAL (CA) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000050580-A2 | COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX | UNIVERSITE DE MONTREAL (CA) | 2000-08-31 | — | — | WO | disclosed |
| US-5403824-A | Administering a opioid, opioid-degrading enzyme inhibitor or enkephalin secretagogues or mixtures thereof; side effect reduction | THE PROCTER & GAMBLE COMPANY (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0280627-B1 | DERIVATIVES OF N-SUBSTITUTED ALPHA-MERCAPTOMETHYL-BENZENE-PROPANAMIDE, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICINES AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1993-04-21 | — | — | EP | disclosed |
| US-4839358-A | ANALGESICS, ANTIDEPRESSANTS, ANTIANXIETY AGENTS | ROUSSEL UCLAF (FR) | 1989-06-13 | — | — | US | disclosed |
| EP-0280627-A2 | Derivatives of N-substituted alpha-mercaptomethyl-benzene-propanamide, process for their preparation, their use as medicines and compositions containing them | ROUSSEL-UCLAF (FR) | 1988-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234518-A1 | Composition, methods and reagents for the synthesis of a soluble form of human PHEX | TPX2, PHPT1, BMX | CPA3 281/4885FOLH1 32/4885MME 353/4885 |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | MME, CTSC, REN | CPA3 63/4885FOLH1 346/4885MME 1/4885 |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | CPA3 63/4885FOLH1 346/4885MME 1/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CPA3 54/4885FOLH1 992/4885MME 1/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | CPA3 89/4885FOLH1 1095/4885MME 1/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | CPA3 71/4885FOLH1 977/4885MME 1/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | CPA3 54/4885FOLH1 992/4885MME 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.